Hyperbaric oxygen treatment results in a group of Turkish central retinal artery occlusion patients with a combined presence of thrombophilic mutations.

What Researchers Did

Researchers evaluated hyperbaric oxygen therapy outcomes and thrombophilic mutations in eleven patients with non-arteritic central retinal artery occlusion.

What They Found

Six of eleven patients (54%) responded to hyperbaric oxygen therapy, with better outcomes for those treated within 12 hours. A high prevalence of MTHFR 677T (72%), MTHFR 1298C (45%), and PAI-1-675 4G (91%) alleles was observed, suggesting a combination of mutations may contribute to central retinal artery occlusion.

What This Means for Canadian Patients

Canadian patients experiencing central retinal artery occlusion might benefit from timely hyperbaric oxygen therapy to improve visual acuity. Understanding the role of combined thrombophilic mutations could help in personalized risk assessment and management strategies.

Canadian Relevance

This study was conducted in Turkey and has no direct Canadian connection.

Study Limitations

The small sample size of eleven patients limits the generalizability of these findings.